AndroGel Adolescent (12 to 17) Transition to Adult Care

Why the Transition From Pediatric to Adult Care Matters

Moving an adolescent off a pediatric endocrinology service is not a single appointment. It is a clinical process that spans months and carries real risk if managed carelessly. Young men with hypogonadism who lose follow-up during this window show higher rates of therapy discontinuation, subtherapeutic testosterone levels, and reduced bone mineral density compared with those who complete a structured handoff.

A 2018 review in the Journal of Clinical Endocrinology and Metabolism found that up to 40% of adolescents with chronic endocrine conditions experience a gap in care during the transition to adult services, and that gap is independently associated with worsened disease-specific outcomes [1]. For testosterone-dependent patients, even a 6-month interruption can allow bone accrual to stall at a time when peak bone mass is still being established.

The Unique Pharmacology Problem in Adolescents

AndroGel is FDA-approved only for adult males with hypogonadism. Its use in patients under 18 is off-label, which means the pediatric team has typically been titrating dose empirically against age-appropriate testosterone ranges rather than adult reference intervals [2]. Once the patient turns 18, the target changes. Adult reference ranges for total testosterone run approximately 300 to 1,000 ng/dL, with most clinical guidelines targeting 400 to 700 ng/dL for replacement therapy [3].

A dose calibrated to produce 350 ng/dL in a 16-year-old may be inadequate, or paradoxically excessive, at 19, depending on endogenous production status. This means the adult provider cannot simply continue the pediatric prescription unchanged.

Who Should Conduct the Handoff

The sending provider is almost always a pediatric endocrinologist. The receiving provider should be an adult endocrinologist, a urologist with andrology expertise, or a primary care physician with documented TRT training. The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism specifies that ongoing testosterone therapy in adults requires a clinician who can interpret gonadotropin patterns, manage erythrocytosis, and screen appropriately for prostate pathology [3].

Confirming the Diagnosis Before Continuing Therapy

The most consequential step at transition is re-evaluating whether the original diagnosis still holds. Not every adolescent who needed testosterone at 14 has permanent hypogonadism at 18.

Constitutional Delay of Growth and Puberty

Constitutional delay of growth and puberty (CDGP) is the most common reason adolescent males receive short-course testosterone. CDGP is self-resolving. The Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology both recommend a 3-to-6-month off-treatment trial at or near age 18 in patients whose original diagnosis was CDGP rather than a structural or genetic cause of hypogonadism [4].

During the off-treatment trial, serum LH, FSH, and total testosterone are drawn after 4 to 6 weeks off gel to assess the hypothalamic-pituitary-gonadal (HPG) axis. If morning total testosterone exceeds 300 ng/dL with appropriate gonadotropin rise, ongoing therapy may not be required.

Permanent Hypogonadism: Klinefelter and Other Causes

Patients with Klinefelter syndrome (47,XXY), bilateral anorchia, pituitary tumor history, or confirmed primary hypogonadism do not have a recoverable HPG axis. These patients transition directly to adult dosing without an off-treatment trial. Klinefelter syndrome affects approximately 1 in 660 male births and is the most common genetic cause of male hypogonadism [5].

For these patients, the transition visit should include a karyotype confirmation in the chart, documentation of the pituitary MRI result (if done), and a fresh DXA scan to establish adult baseline bone mineral density.

Dose Conversion at Transition: AndroGel 1% vs. 1.62%

This is where medication errors happen most often. The two commercially available AndroGel formulations deliver different testosterone amounts per pump actuation or per gram of gel, and they cannot be substituted on a one-to-one basis.

AndroGel 1% Dosing

AndroGel 1% is supplied in unit-dose packets (25 mg and 50 mg) and metered-dose pumps (each pump delivers 12.5 mg testosterone). The FDA-approved starting adult dose is 50 mg applied once daily, with titration to 100 mg if serum testosterone remains below the normal range at 14 days [2].

AndroGel 1.62% Dosing

AndroGel 1.62% delivers 20.25 mg testosterone per pump actuation. The adult starting dose is 40.5 mg (2 pumps) once daily, titratable up to 81 mg (4 pumps) [2]. A patient who moves from a pediatric formulary that stocked 1% to an adult pharmacy carrying 1.62% may receive a different testosterone dose than intended if the prescriber writes only "continue same number of pumps."

The adult provider should recalculate milligram dose, not pump count, at every formulary transition.

Timing the First Post-Transition Lab Draw

FDA labeling for both formulations instructs that serum testosterone should be measured 2 hours after gel application, at least 14 days after any dose change [2]. At the transition visit, order labs at the 14-day mark post any dose adjustment, not at the routine 3-month interval that may have been used in pediatric care.

Safety Monitoring Protocol for the First Adult Year

The first 12 months of adult care carry heightened monitoring requirements because baseline values shift with skeletal and muscle maturation, and because several adverse effects accumulate with duration of therapy.

Hematocrit and Polycythemia

Testosterone stimulates erythropoiesis. Hematocrit should be checked at baseline, at 3 months, and then every 6 months once stable. The Endocrine Society guideline recommends withholding therapy and evaluating for hypoxia or sleep apnea if hematocrit exceeds 54% [3]. Adolescents transitioning to full adult dosing may see a hematocrit rise simply from the dose increase, independent of any pathological process.

Bone Mineral Density

Males with delayed or absent puberty accumulate less trabecular and cortical bone than age-matched peers. A DXA scan at transition provides the adult-care team a baseline. If Z-score is below -2.0 at the lumbar spine or femoral neck, the treating clinician should consider a formal metabolic bone consultation alongside testosterone therapy [6].

Testicular and Prostatic Monitoring

Testosterone gel does not suppress spermatogenesis as reliably as injectable testosterone esters, but gonadotropin suppression still occurs with supraphysiologic levels. If fertility preservation is a priority, a semen analysis at transition is reasonable. PSA measurement is appropriate starting at age 18, though prostate cancer risk in this demographic is negligible; the value lies in establishing a baseline [3].

Building the Transition Transfer Document

A structured transfer document reduces the risk of diagnostic and dosing errors. The document should include the following elements as a minimum standard.

Clinical History Elements

The transfer document must contain the original diagnosis with supporting lab values (morning total testosterone at nadir, LH, FSH, karyotype if done), the date therapy started, and every dose change with the clinical rationale for each change. Growth charts from the pediatric record should accompany the document, because final height and bone age data inform the interpretation of future DXA results.

Current Medication Details

The exact formulation (1% or 1.62%), dose in milligrams per day, number of pump actuations, application site, and last serum testosterone result (with the time of draw relative to application) must all be specified. Ambiguous prescriptions are the single most common source of AndroGel dosing errors at transition points.

Pending Clinical Questions

If the pediatric team was uncertain whether the patient would need lifelong therapy, that uncertainty should be documented explicitly so the adult provider knows to perform an off-treatment trial. Unanswered questions should not be buried in a chart note; they belong in the transition summary.

The American Academy of Pediatrics' 2018 clinical report on health care transition recommends a standardized transfer package and a minimum of one joint visit (outgoing and incoming provider together, or by structured asynchronous handoff) before the final pediatric appointment [7].

Skin Transfer and Safety Warnings: What Adult Partners Need to Know

AndroGel carries an FDA black-box warning for secondary exposure. Testosterone gel transfers from application sites to skin-to-skin contact, and cases of virilization in female partners and children have been reported [2]. This warning applies to adult patients just as it did during adolescent use.

At the transition visit, the adult provider should re-counsel the patient and any household contacts on application site coverage (wearing a shirt after application, washing hands thoroughly, covering the site before physical contact). The FDA has documented cases where toddlers developed premature pubic hair and clitoral enlargement after repeated secondary gel exposure [2].

Clinicians should ask about new intimate partners and cohabiting children at each visit, not only at initiation.

Psychosocial Dimensions of Transitioning Care

Identity and Medication Adherence

Adolescents on testosterone for hypogonadism often report that the medication is tied to their sense of physical normalcy. A break in prescription coverage during the transition period, whether from insurance lapses, provider gaps, or pharmacy issues, can produce abrupt hypogonadism symptoms: fatigue, low mood, reduced libido, and hot flashes. These symptoms can be misattributed to depression or anxiety, delaying correct management.

A structured transition plan that addresses prior authorization requirements with the adult insurer before the last pediatric visit prevents most coverage gaps.

Shared Decision-Making on Fertility

Adult testosterone therapy suppresses the HPG axis and reduces intratesticular testosterone, which is required for spermatogenesis. A 2020 study in Fertility and Sterility found that exogenous testosterone use is associated with azoospermia or severe oligospermia in approximately 65% of men after 6 months of use [8]. At transition, the provider should document a fertility conversation. If the patient wants to preserve fertility options, referral to a reproductive urologist for sperm banking or discussion of alternative therapies (clomiphene citrate, hCG) is appropriate before adult dosing is established.

The Endocrine Society guideline states directly: "We recommend against starting testosterone therapy in men who are currently trying to conceive" [3].

Practical Clinical Checklist for the Adult Receiving Provider

The following steps should occur at or before the first adult-care appointment.

Obtain and review the full pediatric transfer document. Confirm the original diagnosis and whether an off-treatment trial is indicated. Recalculate the milligram dose if the patient is switching formulations. Order baseline labs: total testosterone (2 hours post-application), free testosterone, LH, FSH, hematocrit, hemoglobin, PSA, and a complete metabolic panel. Schedule a DXA scan if bone density has not been assessed in the prior 2 years. Re-counsel on skin transfer precautions and application technique. Document a fertility discussion. Set the next monitoring appointment for 3 months, not 6.

Getting this first visit right reduces the probability of subtherapeutic levels, erythrocytosis, and loss to follow-up during the highest-risk window for this population.